Analysts have adjusted their price target for Standard BioTools downward from $1.78 to $1.55. They cited updated expectations around revenue growth and profit margins.
What's in the News
- Molecular Instruments and Standard BioTools have entered a strategic collaboration to develop next-generation Imaging Mass Cytometry workflows using HCR imaging technologies. This partnership enables amplified detection for both RNA and protein and provides greater workflow flexibility (Key Developments).
- The partnership introduces the HCR HiFi Encoder, which allows researchers to use any primary antibody for robust protein imaging and facilitates visualization of low-abundance markers (Key Developments).
- Standard BioTools affirmed its earnings guidance for the fiscal year 2025, with expected combined revenue between $165 million and $175 million, and revenue from continuing operations projected at $78 million to $83 million (Key Developments).
Valuation Changes
- Fair Value Estimate has fallen from $1.78 to $1.55.
- Discount Rate has risen slightly, moving from 7.26% to 7.84%.
- Revenue Growth projection has declined marginally from -20.92% to -20.99%.
- Net Profit Margin forecast has improved from 14.21% to 15.66%.
- Future P/E Ratio has dropped significantly from 74.56x to 59.47x.
Have other thoughts on Standard BioTools?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.